<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>RHODIA, A FRENCH CHEMICAL MAKER, IS ACQUIRING CHIREX</title>
    <meta content="MB005314" name="slug"/>
    <meta content="25" name="publication_day_of_month"/>
    <meta content="7" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Tuesday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="4" name="print_page_number"/>
    <meta content="C" name="print_section"/>
    <meta content="1" name="print_column"/>
    <meta content="Business" name="online_sections"/>
    <meta content="Correction Appended" name="banner"/>
    <meta content="20000727T000000" name="correction_date"/>
    <docdata>
      <doc-id id-string="1217657"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <series series.name="COMPANY NEWS"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Mergers, Acquisitions and Divestitures</classifier>
        <org class="indexing_service">ChiRex Inc</org>
        <org class="indexing_service">Rhodia Sa</org>
        <person class="indexing_service">Skomial, Marcin</person>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Pharmaceutical, Biotechnology and Science</classifier>
        <classifier class="online_producer" type="general_descriptor">Mergers, Acquisitions and Divestitures</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Finances</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000725T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9501E6DA103AF936A15754C0A9669C8B63" item-length="126" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>RHODIA, A FRENCH CHEMICAL MAKER, IS ACQUIRING CHIREX</hl1>
      </hedline>
      <byline class="print_byline">By Marcin Skomial</byline>
      <byline class="normalized_byline">Skomial, Marcin</byline>
      <abstract>
        <p>ChiRex Inc, provider of advanced product development services and manufacturing to pharmaceutical industry, agrees to be acquired by French chemical maker Rhodia SA, biggest maker of ingredients in aspirin, for about $510 billion (S)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>ChiRex Inc. said yesterday that it had agreed to be acquired by the French chemical company Rhodia S.A. for $31.25 a share, or a total of about $510 billion. Rhodia, the biggest maker of ingredients in aspirin, expects to start the offer by Aug. 4. Chirex, which had revenue of $147 million last year, provides advanced product development services and manufacturing to the pharmaceutical industry. It is based in Stamford, Conn. Chirex's shares rose $10.5625 each yesterday, to $30.6875, in Nasdaq trading.</p>
        <p>Marcin Skomial (NYT)</p>
      </block>
      <block class="full_text">
        <p>ChiRex Inc. said yesterday that it had agreed to be acquired by the French chemical company Rhodia S.A. for $31.25 a share, or a total of about $510 billion. Rhodia, the biggest maker of ingredients in aspirin, expects to start the offer by Aug. 4. Chirex, which had revenue of $147 million last year, provides advanced product development services and manufacturing to the pharmaceutical industry. It is based in Stamford, Conn. Chirex's shares rose $10.5625 each yesterday, to $30.6875, in Nasdaq trading.</p>
        <p>Marcin Skomial (NYT)</p>
        <p>COMPANY NEWS  Correction:  July 27, 2000, Thursday  A report in the Company News column of Business Day on Tuesday about the purchase of ChiRex, a manufacturer for the pharmaceutical industry, by the French chemical company Rhodia misstated the price. It is $510 million, not $510 billion.</p>
      </block>
      <block class="correction_text">
        <p>Correction: July 27, 2000, Thursday</p>
        <p>A report in the Company News column of Business Day on Tuesday about the purchase of ChiRex, a manufacturer for the pharmaceutical industry, by the French chemical company Rhodia misstated the price. It is $510 million, not $510 billion.</p>
        <p>&lt;br&gt;</p>
        <p>&lt;br&gt;</p>
      </block>
    </body.content>
  </body>
</nitf>
